Allergan, Inc. (NYSE:AGN), Director Louis Lavigne, Jr. sold 5,400 shares of the stock on the open market in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $125.79, for a total value of $679,266.00. Following the sale, the director now directly owns 12,723 shares of the company’s stock, valued at approximately $1,600,426. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed throughthis link. Allergan, Inc. (NYSE:AGN), shares after opening at $164.26 moved to $167.04 on last trade day and at the end of the day closed at $166.61. Company price to sales ratio in past twelve months was calculated as 7.91 and price to cash ratio as 13.66. Allergan, Inc. (NYSE:AGN), showed a positive weekly performance of 26.74%.
Mylan Inc (NASDAQ:MYL), CEO Heather Bresch unloaded 75,000 shares of the stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $46.07, for a total value of $3,455,250.00. Following the completion of the sale, the chief executive officer now directly owns 293,418 shares of the company’s stock, valued at approximately $13,517,767. The sale was disclosed in a document filed with the SEC, which is available at this link. Mylan Inc (NASDAQ:MYL), shares advanced 0.14% in last trading session and ended the day on $50.35. Mylan Inc (NASDAQ:MYL), return on equity ratio is recorded as 20.90% and its return on assets is 4.80%. Mylan Inc (NASDAQ:MYL), yearly performance is 75.50%.
Questcor Pharmaceuticals Inc (NASDAQ:QCOR), CEO Don M. Bailey sold 40,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $62.71, for a total transaction of $2,508,400.00. The sale was disclosed in a filing with the SEC, which is available at this link. Questcor Pharmaceuticals Inc (NASDAQ:QCOR), shares moved up 2.79% in last trading session and was closed at $82.30, while trading in range of $ 81.00 – 83.89. Questcor Pharmaceuticals Inc (NASDAQ:QCOR), year to date (YTD) performance is 52.55%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Director Donald D. Belcher sold 1,905 shares of Arena Pharmaceuticals stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $6.45, for a total transaction of $12,287.25. Following the completion of the transaction, the director now directly owns 68,728 shares in the company, valued at approximately $443,296. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), weekly performance is -2.06%. On last trading day company shares ended up $6.17. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), distance from 50-day simple moving average (SMA50) is -6.12%. Analysts mean target Price for the company is $7.83.
Leave a Reply